Connect Biopharma (NASDAQ:CNTB – Get Free Report) and Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.
Risk and Volatility
Connect Biopharma has a beta of -0.16, meaning that its share price is 116% less volatile than the S&P 500. Comparatively, Inhibrx Biosciences has a beta of 3.81, meaning that its share price is 281% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Connect Biopharma and Inhibrx Biosciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Connect Biopharma | 1 | 0 | 7 | 0 | 2.75 |
| Inhibrx Biosciences | 1 | 2 | 2 | 1 | 2.50 |
Institutional and Insider Ownership
58.7% of Connect Biopharma shares are held by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are held by institutional investors. 22.6% of Connect Biopharma shares are held by company insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Connect Biopharma and Inhibrx Biosciences”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Connect Biopharma | $60,000.00 | 913.07 | -$55.48 million | ($1.19) | -0.73 |
| Inhibrx Biosciences | $1.30 million | 1,075.81 | -$140.05 million | ($8.88) | -10.70 |
Connect Biopharma has higher earnings, but lower revenue than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Connect Biopharma and Inhibrx Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Connect Biopharma | N/A | -165.41% | -121.58% |
| Inhibrx Biosciences | N/A | -563.90% | -83.48% |
Summary
Connect Biopharma beats Inhibrx Biosciences on 8 of the 14 factors compared between the two stocks.
About Connect Biopharma
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.
About Inhibrx Biosciences
Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.
Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
